trial

Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole

NCTId NCT02219009
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 67 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2015-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
67 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2014-08
Primary completion
2015-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
MIND1 System

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Timothy Peters-Strickland, MDStudy Director

Sites

0 total

Linked catalysts

1
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1 — primary completion2015-07

Facts & assertions

4 sourced
Enrollment
67
Phase
PHASE2
Primary Completion Date
2015-07
Status
COMPLETED
relationships
The graph out of here
drug
MIND1 System
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Treatment Adherence and Compliance
indication
Nervous System Diseases
indication
Mental Disorder
indication
investigator
Timothy Peters-Strickland, MD
person